-
Is GHK-Cu FDA Approved? Drug Approval vs Cosmetic and Compounding Records
GHK-Cu cosmetic use, FDA drug approval, and 503A compounding categories are different records. Review the dated official sources and limitations.
-
What Color Is Tirzepatide? Why Appearance Cannot Confirm Identity
FDA labeling describes a specific tirzepatide solution as clear and colorless to slightly yellow. Learn why appearance cannot confirm peptide identity.
-
Retatrutide Side Effects: What Clinical Trials Have Actually Reported
Review adverse events reported in retatrutide Phase 2 and Phase 3 trials, with group-level context, evidence limits, and source-linked records.
-
Survodutide vs Retatrutide: Receptors, Trial Designs, and Evidence Limits
Compare survodutide and retatrutide by receptor targets, Phase 2 trial design, evidence boundaries, and why separate trials are not head-to-head proof.
-
Semax Half-Life: What Stability Studies Can and Cannot Tell Us
A validated human Semax half-life is not established in the cited literature. Learn what enzyme and biological-media stability studies actually show.
-
TB-500 Half-Life: Why the Published Answer Is Still Uncertain
No reliable published human half-life is established for Ac-LKKTETQ. See why TB-500 detection and thymosin beta-4 data cannot supply it.
-
Cagrilintide Half-Life: What Human Pharmacokinetic Studies Report
A Phase 1b study reported a 159-195 hour cagrilintide half-life. Learn what the range measures and why it is not a batch specification.
-
Retatrutide Half-Life: What the Six-Day Estimate Actually Means
Retatrutide half-life is approximately six days in early human studies. Learn what the estimate measures, its source, and its evidence limits.
-
Cagrilintide Clinical Trials: What Monotherapy and CagriSema Studies Actually Test
Compare cagrilintide monotherapy and CagriSema trials by intervention, comparator, population, duration, endpoint, phase, and evidence limits.
-
Semaglutide Ingredients: Active Peptide, Excipients, and Product Form
Learn why semaglutide is the active peptide while injection, tablet, compounded, and research-material ingredient records require separate sources.
-
Is Retatrutide FDA Approved? Current Status and How to Verify It
Retatrutide is not FDA approved as of October 23, 2026. Learn how FDA records, trial status, labels, and COAs answer different questions.
-
Tirzepatide Half-Life: How Long Does It Stay in Your System?
Learn what tirzepatide’s approximately five-day half-life measures, why it does not mean complete elimination, and which evidence supports it.
